20721-78-2

Basic information

• Product Name: 4-methylmorpholin-3-one
• Synonyms: 3-morpholinone, 4-methyl-; 4-Methylmorpholin-3-one
• CAS NO: 20721-78-2
• Molecular Formula: C₅H₉NO₂
• Molecular Weight: 115.1305
• Mol File: 20721-78-2.mol

Chemical Properties

• Boiling Point: 240.9°C at 760 mmHg
• Flash Point: 99.5°C
• Density: 1.095g/cm³
• Vapor Pressure: 0.0369mmHg at 25°C
• Refractive Index: 1.454
• CAS DataBase Reference: 4-methylmorpholin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methylmorpholin-3-one(20721-78-2)
• EPA Substance Registry System: 4-methylmorpholin-3-one(20721-78-2)

Safety Data

• Hazardous Substances Data: 20721-78-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Methylmorpholin-3-one is utilized as a key building block in the creation of various pharmaceuticals due to its ability to form a wide range of chemical bonds, contributing to the development of new drugs with diverse therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 4-Methylmorpholin-3-one serves as a crucial intermediate, facilitating the synthesis of compounds that are integral to the development of pesticides and other agricultural chemicals, thereby enhancing crop protection and yield.
Used as a Solvent in Organic Synthesis:
4-Methylmorpholin-3-one is employed as a solvent in organic synthesis processes, providing a medium that supports a variety of chemical reactions, which is essential for the production of complex organic compounds.
Used as an Intermediate in Organic Synthesis:
Beyond its role as a solvent, 4-Methylmorpholin-3-one also functions as an intermediate in organic synthesis, participating directly in chemical reactions to form desired end products, which underscores its multifaceted utility in the realm of chemical manufacturing.

Upstream product

• 79-04-9 chloroacetyl chloride 
• 109-83-1 (2-hydroxyethyl)(methyl)amine 
• 105-39-5 chloroacetic acid ethyl ester 
• 109-02-4 4-methyl-morpholine 
• 109-11-5 morpholine-3-one 
• 74-88-4 methyl iodide 

Downstream Products

• 153807-04-6 (+)-(1R,4R,5R,6S)-5,6-dihydroxybicyclo<2.2.1>heptan-2-one 
• 225506-82-1 4-methyl-2-<1-(4-methoxyphenyl)-1-(phenylamino)-methyl>-3-morpholinone 
• 225506-79-6 4-methyl-2-<1-(4-chlorophenyl)-1-(phenylamino)-methyl>-3-morpholinone 
• 444792-77-2 2-<1-hydroxy-1-(4-methoxyphenyl)methyl>-4-methyl-3-morpholinone 
• 225506-76-3 4-methyl-2-(1-phenylamino-1-phenylmethyl)-3-morpholinone 
• 128407-14-7 2-<(benzoylamino)(phenyl)methyl>-4-methyl-3-morpholinone 
• 225506-81-0 4-methyl-2-<1-(3-methoxyphenyl)-1-(phenylamino)-methyl>-3-morpholinone 
• 225506-77-4 4-methyl-2-<1-(2-chlorophenyl)-1-(phenylamino)-methyl>-3-morpholinone 
• 225506-78-5 4-methyl-2-<1-(3-chlorophenyl)-1-(phenylamino)-methyl>-3-morpholinone 
• 128407-15-8 2-(1-benzoylamino-1,1-diphenylmethyl)-4-methyl-3-morpholinone 
• 120829-29-0 2-<1-hydroxy-1,1-diphenylmethyl>-4-methyl-3-morpholinone 

Relevant articles and documents

6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER

The present invention discloses 6,7-dihydro-5H-pyrido[2,3- c]pyridazine, 1,2,3,4-tetrahydroquinoline, 1H-indole, 3,4- dihydro-2H-1,4-benzoxazine, 1H-pyrrolo[2,3-b]pyridin-1-yl, 7H- pyrrolo[2,3-c]pyridazine, 5H,6H,7H,8H,9H-pyridazino[3,4-b]azepine derivatives and related compounds of formula (I) as Bcl-xL protein inhibitors for use as pro-apoptotic agents for treating cancer, autoimmune diseases or immune system diseases. Formula (I). The description discloses the preparation of exemplary compounds (e.g. pages 113 to 354 examples 1 to 221) as well as pharmacological studies with relevant data (e.g. pages 355 to 367; examples A to E; tables 1 to 5). Exemplary compounds are e.g. 2-{6-[(1,3-benzothiazol-2-yl) amino]-1,2,3,4-tetrahydroquinolin-1-yl}-1,3-thiazole-4-carboxylic acid (example 1) or e.g. 3-{1-[(adamantan-1-yl)methyl]-5- methyl-1H-pyrazol-4-yl}-6-{3-[(1,3-benzothiazol-2-yl)amino]-4- methyl-5H,6H,7H,8H-pyrido[2,3-c]pyridazin-8-yl]pyridine-2-carboxylic acid (example 24).

3-(Imidazolyl)-2-alkoxypropanoic acids

Compounds according to formula (I) wherein n is 0-3, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and optionally substituted C1-6 alkyl, or R5 and R8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.

DI- OR TRIPEPTIDE RENIN INHIBITORS CONTAINING LACTAM CONFORMATIONAL RESTRICTION IN ACHPA

Enzyme di-or tripeptides of the formula: STR1 and analogs thereof which inhibit renin and are useful for treating various forms of renin-associated hypertension, hyperaldosteronism and congestive heart failure; compositions containing these renin-inhibitory peptides, optionally with other antihypertensive agents; and methods of treating hypertension, hyperaldosteronism or congestive heart failure or of establishing renin as a causative factor in these problems which employ these novel peptides.

GIF OXIDATION OF SOME ALICYCLIC AMINES

The Gif oxidation of seven alicyclic tertiary amines leads essentially to the formation of lactams.The structure of the products present in trace amounts supports the mechanistic hypothesis previously advanced.The structures of the oxidation products were investigated using high performance GC-MS system.

PREPARATION OF LACTAMS VIA OXIDATION OF CYCLIC, TERTIARY AND SECONDARY AMINES WITH Hg(II)-EDTA COMPLEX IN ALKALINE MEDIUM

Oxidation of N-alkylpiperidines and other cyclic, tertiary amines with Hg(II)-EDTA complex in basic solution yields lactams, similar oxidation of N-hydroxypiperidines gives hydroxamic acids (presumably via nitrones) and oxidation of N-unsubstituted piperidines affords lactams, probably via 1-piperidine trimers.